scholarly journals The Effect of Atrovastatin on Inflammatory Markers in Sulfur Mustard Gas Induced Bronchitis; A Randomized Double-Blinded, Placebo-Controlled Clinical Trial

2020 ◽  
Author(s):  
Behrooz Momeni ◽  
Saeed Nazer ◽  
Seyed Masoom Masoompour ◽  
Bita Geramizadeh ◽  
Seyed Vahid Sajadi
Keyword(s):  
Clinical Trial ◽  
Chronic Bronchitis ◽  
Inflammatory Markers ◽  
Sulfur Mustard ◽  
Controlled Clinical Trial ◽  
Mustard Gas ◽  
Tnf Α ◽  
Gas Inhalation ◽  
Mean Differences ◽  
Double Blinded

Abstract Background: This study was conducted to evaluate the anti-inflammatory effect of atorvastatin in patients with chronic bronchitis due to sulfur mustard gas inhalation. Methods: In this randomized double-blinded clinical trial we enrolled patients with chronic bronchitis due to sulfur mustard gas inhalation. Ninety man aged between 45 to 75 years with diagnosed of chronic bronchitis due to exposure to mustard gas during the Iran-Iraq war, were randomly assigned to receive either atorvastatin (40 mg) or placebo, given orally once a day for 3 months. The interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), procalcitonin, highly sensitive CRP, and COPD assessment test (CAT) score in both groups compared with each other and baseline data. Results: After 12 weeks of using atorvastatin (n=40), the level IL-6 decreased significantly (p=0.03) without any significant differences in the level of TNF-α, high sensitive CRP, and procalcitonin (P=0.31, p=0.78, and p=0.08). In placebo group (n=38), both procalcitonin and IL-6 significantly decreased after 12 weeks (P=0.002 and p<0.001), but levels of high sensitive CRP did not differ significantly and the level of TNF-α increased (p=0.006). The mean differences in levels of TNF- α, IL-6, high sensitive CRP, and procalcitonin did not differ statistically significant between the study groups after 12 weeks. Although after 12 weeks of study in both groups the CAT score have had appreciably high magnitude decrease (P<0.001), but its mean differences change wasn't significant between group (P=0.71). Conclusions: Administration of 40 mg atorvastatin for 3 months although could not significantly change systemic inflammatory markers or quality of life in mustard gas induced chronic bronchitis.Trial registration: IRCT, IRCT138904144312N1. Registered 16 August 2014, https://en.irct.ir/trial/4577

The effect of atorvastatin on inflammatory markers in sulfur mustard gas induced bronchitis; a randomized double-blinded, placebo-control clinical trial

2020 ◽  
Author(s):  
Behrooz Momeni ◽  
Saeed Nazer ◽  
Seyed Masoom Masoompour ◽  
Bita Geramizadeh ◽  
Seyed Vahid Sajadi
Keyword(s):  
Clinical Trial ◽  
Chronic Bronchitis ◽  
Inflammatory Markers ◽  
Sulfur Mustard ◽  
Mean Difference ◽  
Placebo Control ◽  
Mustard Gas ◽  
Tnf Α ◽  
Mean Differences ◽  
Double Blinded

Abstract Background: This study was performed to evaluate the anti-inflammatory effect of atorvastatin in patients with chronic bronchitis, exposed to sulfur mustard gas. Methods: In this randomized double-blinded clinical trial we recruited patients with chronic bronchitis after exposure to sulfur mustard gas. Ninety men 45-75 years old diagnosed with chronic bronchitis after exposure to mustard gas during the Iran-Iraq war, were randomly assigned to receive either atorvastatin (40 mg) or placebo once a day for 3 months. The interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), procalcitonin, highly sensitive CRP and COPD assessment test (CAT) score was compared at baseline and after 12 weeks. Results: After consuming atorvastatin for 12 weeks, IL-6 level (mean difference [95%CI]; 0.2[-0.05, 0.5]), TNF-α(mean difference [95%CI]; -0.07[-0.2, 0.07]), high sensitive CRP(mean difference [95%CI] -0.1[-1.2, 0.9]), and procalcitonin (mean difference [95%CI]; 0.003[-0.02, 0.03]) did not change significantly. However, in the placebo group, only IL-6 (mean difference [95%CI]; 0.6[0.2, 1.05]) decreased significantly after 12 weeks, but levels of high sensitive CRP (mean difference [95%CI]; -0.3[-1.4, 0.8]) TNF-α (mean difference [95%CI]; -0.2[-0.34, -0.06]) and procalcitonin (mean difference [95%CI]; 0.02[-0.001, 0.04]) did not change significantly. After 12 weeks, the mean differences in TNF- α, IL-6 level, high sensitive CRP, procalcitonin, and CAT score did not significantly differ between the two groups. Conclusions: The administration of 40 mg atorvastatin for 3 months did not significantly change the inflammatory markers or the quality of life of patients exposed to mustard gas with chronic bronchitis.Trial registration: IRCT, IRCT138904144312N1. Registered 16 August 2014, https://en.irct.ir/trial/4577

scholarly journals The effect of atorvastatin on inflammatory markers in sulfur mustard gas induced bronchitis: a randomized double-blinded, placebo-control clinical trial

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Behrooz Momeni ◽  
Saeed Nazer ◽  
Seyed Masoom Masoompour ◽  
Bita Geramizadeh ◽  
Seyed Vahid Sajadi
Keyword(s):  
Clinical Trial ◽  
Chronic Bronchitis ◽  
Inflammatory Markers ◽  
Sulfur Mustard ◽  
Mean Difference ◽  
Placebo Control ◽  
Mustard Gas ◽  
Tnf Α ◽  
Mean Differences ◽  
Double Blinded

Abstract Background This study was performed to evaluate the anti-inflammatory effect of atorvastatin in patients with chronic bronchitis, exposed to sulfur mustard gas. Methods In this randomized double-blinded clinical trial we recruited patients with chronic bronchitis after exposure to sulfur mustard gas. Ninety men 45–75 years old diagnosed with chronic bronchitis after exposure to mustard gas during the Iran-Iraq war, were randomly assigned to receive either atorvastatin (40 mg) or placebo once a day for 3 months. The interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), procalcitonin, highly sensitive CRP and COPD assessment test (CAT) score was compared at baseline and after 12 weeks. Results After consuming atorvastatin for 12 weeks, IL-6 level (mean difference [95%CI]; 0.2 [− 0.05, 0.5]), TNF-α (mean difference [95%CI]; − 0.07 [− 0.2, 0.07]), high sensitive CRP (mean difference [95%CI] − 0.1 [− 1.2, 0.9]), and procalcitonin (mean difference [95%CI]; 0.003 [− 0.02, 0.03]) did not change significantly. However, in the placebo group, only IL-6 (mean difference [95%CI]; 0.6 [0.2, 1.05]) decreased significantly after 12 weeks, but levels of high sensitive CRP (mean difference [95%CI]; − 0.3 [− 1.4, 0.8]) TNF-α (mean difference [95%CI]; − 0.2 [− 0.34, − 0.06]) and procalcitonin (mean difference [95%CI]; 0.02 [− 0.001, 0.04]) did not change significantly. After 12 weeks, the mean differences in TNF- α, IL-6 level, high sensitive CRP, procalcitonin, and CAT score did not significantly differ between the two groups. Conclusions The administration of 40 mg atorvastatin for 3 months did not significantly change the inflammatory markers or the quality of life of patients exposed to mustard gas with chronic bronchitis. Trial registration: IRCT, IRCT138904144312N1. Registered 16 August 2014, https://en.irct.ir/trial/4577.

Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial

2021 ◽  
Vol 21 ◽  
Author(s):  
Bijan Helli ◽  
Hadis Gerami ◽  
Maria Kavianpour ◽  
Habib Heybar ◽  
Seyed Kianoosh Hosseini ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Clinical Trial ◽  
Lipid Profile ◽  
Inflammatory Markers ◽  
Interleukin 1 ◽  
Stress Factors ◽  
Inflammatory Factors ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Tnf Α

Background: Curcumin demonstrated many pharmacological effects including antioxidants, anti-inflammation, eliminating free radicals, anti-tumor, lipid regulation, and anti-coagulation. Objective: This study aimed to assess and compare curcumin and nano-curcumin effects on lipid profile, oxidative stress, and inflammatory factors related to patients ‘heart. Method: This randomized, double-blind, placebo-controlled clinical trial was conducted on 90 patients undergoing coronary elective angioplasty which were randomly divided into 3 groups. The doses administered for 8 weeks were a 500 mg capsule of curcumin daily for the first group and an 80 mg capsule of nano-curcumin for the second group. However, the placebo group received capsules like curcumin. Lipid profile, oxidative stress factors, and inflammatory markers were measured at the baseline and end of the experiment. Results: Statistically significant changes were observed in the total cholesterol (TC), triacylglycerol (TG) and low-density lipoprotein cholesterol (LDL-C) in the intervention groups to the control group (p<0.05). Curcumin and nano-curcumin supplementation also improved significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA), Superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), high-sensitivity C-reactive protein (hs-CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in comparison to the placebo (p<0.05). Furthermore, the nano-curcumin group compared to the curcumin group demonstrated significant changes (p<0.05) in TC, TG, SOD, MDA and TNF-α levels. Conclusion: The effects of curcumin on nano formula may be better for cardiac patients due to its high bioavailability.

Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 3-LB ◽  
Author(s):  
PARESH DANDONA ◽  
HUSAM GHANIM ◽  
NITESH D. KUHADIYA ◽  
TANVI SHAH ◽  
JEANNE M. HEJNA ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Clinical Trial ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Additional Treatment ◽  
Controlled Clinical Trial ◽  
Double Blinded

scholarly journals Administration of Apple Polyphenol Supplements for Skin Conditions in Healthy Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Nutrients ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1071
Author(s):  
Toshihiko Shoji ◽  
Saeko Masumoto ◽  
Nina Moriichi ◽  
Yasuyuki Ohtake ◽  
Tomomasa Kanda
Keyword(s):  
Clinical Trial ◽  
Uv Irradiation ◽  
Skin Pigmentation ◽  
Controlled Clinical Trial ◽  
Continuous Administration ◽  
Double Blind ◽  
Healthy Women ◽  
Dependent Relationship ◽  
Skin Conditions ◽  
Double Blinded

This clinical study was performed to evaluate the effects of continuous apple polyphenol (AP) administration on facial skin conditions and pigmentation induced by ultraviolet (UV) irradiation in healthy women participants. Participants (n = 65, age 20–39 years) were randomized to receive tablets containing AP (300 or 600 mg/day) or placebo in a double-blinded, placebo-controlled clinical trial. Continuous administration of AP for 12 weeks significantly prevented UV irradiation induced skin pigmentation (erythema value, melanin value, L value), although a dose-dependent relationship was not clearly observed. In contrast, no significant differences were detected between the groups with regard to water content and trans-epidermal water loss. Our study demonstrated that APs and their major active compounds, procyanidins, have several health benefits. Here, we report that continuous administration of AP for 12 weeks alleviated UV irradiation induced skin pigmentation, when compared with placebo, in healthy women.

Sign in / Sign up

Export Citation Format

Share Document